Neutropaenia complications from Ocrelizumab and Rituximab treatment

Area of Science:

• Neuroimmunology
• Hematology
• Pharmacology

Background:

• Ocrelizumab and rituximab are anti-CD20 monoclonal antibodies used for multiple sclerosis (MS) and other autoimmune diseases.
• Rituximab, a chimeric antibody, predates ocrelizumab and remains a key treatment for various neuroinflammatory and systemic conditions.
• Neutropenia is a rare but serious adverse event associated with both ocrelizumab and rituximab therapies.

Purpose of the Study:

• To characterize the clinical parameters of neutropenia in patients treated with ocrelizumab or rituximab.
• To analyze the severity, duration, and associated infections of neutropenia.
• To inform clinical management and patient counseling regarding B-cell depleting therapies.

Main Methods:

• A case series reporting on 12 patients who developed neutropenia after ocrelizumab or rituximab treatment.
• Analysis of clinical data including neutropenia severity, duration, hospital admission length, infection types, and treatment interventions.
• Review of patient outcomes and recovery from neutropenia.

Main Results:

• Neutropenia occurred as a rare complication in patients receiving ocrelizumab or rituximab.
• The case series details the clinical characteristics, severity, and duration of neutropenia.
• Associated infections and necessary treatments for count recovery were documented.

Conclusions:

• Neutropenia following B-cell depleting therapy is unpredictable and can lead to severe infections.
• Continuous hematological monitoring is crucial for patients on ocrelizumab and rituximab.
• Informed patient counseling is essential for managing the risks associated with these therapies, especially after experiencing neutropenia.